The adverse impacts of CDK6 have been investigated in most gynecologic tumors, including epithelial ovarian cancer and breast cancer, and its activity is always considered as an important point for tumor inhibition during clinical treatment (Dai et al., 2015; Dall'Acqua et al., 2017; Wolff, 2016). The gene discussed is CDK6; the disease is breast cancer.